Loading…
Loading…
IVMED (In Veritas Medical Diagnostics, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
IVMED does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for IVMED and 80,000+ other tickers.
See exactly how IVMED's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IVMED and 80,000+ other tickers.
In Veritas Medical Diagnostics, Inc. operates as a development-stage firm, dedicated to researching and developing medical devices designed for near-patient or point-of-care diagnostic applications. The company's flagship product is a prothrombin monitor, crucial for evaluating blood clotting in patients vulnerable to cardiovascular events and cerebrovascular accidents. Beyond this, In Veritas Medical Diagnostics is actively developing a suite of other innovative products. These include a consumer-oriented device to predict labor onset for maternity planning; a comprehensive biomarker monitor…
No recent news available.